| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.49M | 18.91M | 6.51M | 4.04M | 1.35M | 0.00 |
| Gross Profit | 16.49M | 18.91M | 6.38M | 1.56M | 1.35M | -2.19M |
| EBITDA | -35.70M | -24.12M | -24.10M | -56.46M | -54.95M | -136.56M |
| Net Income | -39.67M | -27.76M | -28.12M | -64.89M | -61.68M | -46.61M |
Balance Sheet | ||||||
| Total Assets | 137.54M | 167.96M | 137.88M | 171.32M | 209.58M | 98.73M |
| Cash, Cash Equivalents and Short-Term Investments | 119.77M | 149.41M | 118.92M | 94.78M | 187.52M | 75.84M |
| Total Debt | 16.86M | 17.22M | 19.73M | 21.97M | 60.37M | 34.28M |
| Total Liabilities | 70.55M | 79.40M | 96.49M | 106.21M | 96.35M | 42.18M |
| Stockholders Equity | 66.98M | 88.56M | 41.39M | 65.50M | 113.83M | 57.09M |
Cash Flow | ||||||
| Free Cash Flow | -42.95M | -37.81M | 20.18M | -69.22M | -26.50M | -47.98M |
| Operating Cash Flow | -42.20M | -36.39M | 21.55M | -68.51M | -26.01M | -47.06M |
| Investing Cash Flow | 13.60M | -4.07M | 4.28M | -702.00K | -425.00K | -924.00K |
| Financing Cash Flow | 70.18M | 70.28M | -2.27M | -30.89M | 136.83M | 14.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $238.97M | ― | -22.84% | ― | 6.05% | 2.24% | |
52 Neutral | $286.18M | -6.35 | -75.99% | ― | 7.59% | -53.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $261.09M | ― | -32.38% | ― | ― | 23.24% | |
45 Neutral | $218.14M | -120.20 | ― | ― | 9.78% | 98.13% | |
40 Underperform | $231.08M | -3.16 | -111.00% | ― | -6.12% | 24.99% |
On October 20, 2025, ProQR Therapeutics announced that it received Clinical Trial Application (CTA) authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 study of its investigational RNA editing oligonucleotide, AX-0810. This study, to be conducted in the Netherlands, will evaluate the safety, tolerability, and pharmacokinetics of AX-0810, which targets NTCP for the treatment of cholestatic diseases. The company also announced a virtual Investor and Analyst Event scheduled for November 3, 2025, to discuss the clinical development of AX-0810 and its potential impact on treating liver diseases.
On August 7, 2025, ProQR Therapeutics N.V. announced its financial results for the second quarter of 2025, ending June 30. The company reported a decrease in revenue compared to the previous year, alongside increased research and development costs, leading to a significant operating loss. This financial performance may impact ProQR’s market positioning and stakeholder confidence as the company navigates the challenges of developing treatments for rare genetic disorders.